Make Drugmakers Pay: England’s Strategy for Cancer Medicines
- Roche, Pfizer concerned new system has no spending limit
- Fund reopens after four-month shutdown under NICE’s oversight
This article is for subscribers only.
England is reopening its Cancer Drugs Fund with a crafty solution to rein in the overspending that blighted its predecessor: make drugmakers pay.
Under new rules, if the fund exceeds its 340 million-pound ($450 million) budget -- as it’s done in the past, overshooting by 37 percent in the final year before the revamp -- pharmaceutical companies will pick up the tab. And there’s no cap on that bill.